[Prevention of development of hepatocellular carcinoma from HCV-associated liver cirrhosis by multi-agents therapy including stronger-neo-minophagen C].
Tarao
K
K
Kanagawa Cancer Center.
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000209:etiology / Q000517:prevention & control*; D002986:Clinical Trials as Topic; D003545:Cysteine / Q000627:therapeutic use*; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use; D005998:Glycine / Q000627:therapeutic use*; D006034:Glycyrrhetinic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D006526:Hepatitis C / Q000150:complications; D006801:Humans; D008103:Liver Cirrhosis / Q000150:complications; D008113:Liver Neoplasms / Q000209:etiology / Q000517:prevention & control*; D012306:Risk; D016896:Treatment Outcome; D014580:Ursodeoxycholic Acid / Q000627:therapeutic use
D000893:Anti-Inflammatory Agents; D004338:Drug Combinations; D004365:Drugs, Chinese Herbal; C063587:juzentaihoto; C018142:saiko-keishi-to; D014580:Ursodeoxycholic Acid; C083319:stronger neominophagen C; D003545:Cysteine; D006034:Glycyrrhetinic Acid; D005998:Glycine